日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development.

FGFR2基因缺失可阻止胰腺导管腺癌的发生发展

期刊:Cancer Research
影响因子:16.6
doi:10.1158/0008-5472.CAN-24-4576
Tonelli Claudia, Deschênes Astrid, Gaeth Victoria A, Jensen Amanda, Vithlani Nandan, Yao Melissa A, Zhao Zhen, Park Youngkyu, Tuveson David A
肿瘤
FGFR2
肿瘤免疫
发表日期：2025
文献求助 收藏

Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting

无论诊断环境如何，少数族裔在胰腺癌治疗方面都面临延误。

期刊:Annals of Surgical Oncology
影响因子:3.5
doi:10.1245/s10434-024-15352-3
Fallon, John; Standring, Oliver; Vithlani, Nandan; Demyan, Lyudmyla; Shah, Manav; Gazzara, Emma; Hartman, Sarah; Pasha, Shamsher; King, Daniel A; Herman, Joseph M; Weiss, Matthew J; DePeralta, Danielle; Deutsch, Gary
胰腺癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care

ASO作者反思：识别和了解弱势群体如何受到胰腺癌治疗延误的影响

期刊:Annals of Surgical Oncology
影响因子:3.5
doi:10.1245/s10434-024-15476-6
Fallon, John; Standring, Oliver; Vithlani, Nandan; Demyan, Lyudmyla; Shah, Manav; Gazzara, Emma; Hartman, Sarah; Pasha, Shamsher; King, Daniel A; Herman, Joseph M; Weiss, Matthew J; DePeralta, Danielle; Deutsch, Gary
胰腺癌
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence

肠易激综合征药物治疗和非药物治疗综述：当前建议和证据

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm13226948
Papale, Anthony J; Flattau, Robert; Vithlani, Nandan; Mahajan, Deepti; Nadella, Sandeep
肠易激综合征
发表日期：2024
文献求助 收藏

Ductal pancreatic cancer interception by FGFR2 abrogation

FGFR2 抑制阻断导管胰腺癌

期刊:
影响因子:
doi:10.1101/2024.10.16.618726
Tonelli, Claudia; Deschênes, Astrid; Gaeth, Victoria; Jensen, Amanda; Vithlani, Nandan; Yao, Melissa A; Zhao, Zhen; Park, Youngkyu; Tuveson, David A
肿瘤免疫
FGFR2
胰腺癌
肿瘤
发表日期：2024
文献求助 收藏